New Cambridge, Office for Alfa Aesar
News Jun 02, 2015
The company opened a new commercial office in Cambridge UK on 1st June 2015.
This is a new and exciting chapter in Alfa Aesar’s UK history, with the opening of this office on the Cambourne Business Park, just west of Cambridge.
Aaron Venables, Head of Global Marketing commented “An important aspect is that it will serve as a platform to further increase our customer focus; with the majority of our top customers in the UK being less than an hour away. Furthermore, Cambridge is one of Europe's leading centres of science and culture and has become the focus for companies turning technology, research and development into tomorrow's commercial successes”.
He added “It will also bring together the sales and marketing personnel currently working remotely in the area into one location. Enabling us to leverage all of the skill sets to drive productivity and efficiency, while building a culture of being results focused and a team spirit that allows us to have fun, produce great quality work and develop together”.
The new office has the potential to become a global Centre of excellence for the commercial functions. The core office opening hours are 8.30am - 6.00pm, Monday to Friday.
Methane Hydrate Formation Studied Using Novel MicroreactorNews
Researchers at the NYU Tandon School of Engineering are using a novel means of studying how methane and water form methane hydrate that allows them to examine discrete steps in the process faster and more efficiently.READ MORE
University of Huddersfield Honorary Award Goes to RSC’s First Woman PresidentNews
The first woman President of the Royal Society of Chemistry, Professor Lesley Yellowlees, will collect an honorary award from University of Huddersfield, which will be presented at the University’s November Award Ceremonies.READ MORE
Drug Discovery Alliance Formed to Help Increase Drug Development Success RateNews
Two prominent preclinical safety companies have launched a unique European alliance to address the high safety-related failure rate in drug development.READ MORE